Soleno Therapeutics Inc

Soleno Therapeutics faces multiple securities‑law investigations while launching a $100 million share‑repurchase, a move that spurred a short‑term stock rally amid growing regulatory scrutiny.

Soleno Therapeutics Inc. has reported a significant increase in revenue and a positive financial performance in Q2, driven by the successful launch of its flagship product VYKAT XR.

Soleno Therapeutics has successfully priced a $200 million public offering to support the launch of its key product VYKAT XR, a rare disease treatment.